Patent ID: 8329640

Claim:
A method of treating lung diseases comprising administering to a patient suffering from said diseases a synthetic peptide in a pharmacologically effective amount selected from the group consisting of (SEQ ID NO: 2) (i) His(Ac)-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr- Thr-Arg-Leu-Arg-Lys-Gln-Met(O)-Ala-Val-Lys-Lys-Tyr- Leu-Asn-Ser-Ile-Leu-Asn, (SEQ ID NO: 3) (ii) His(Ac)-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr- Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr- Leu-Asn-Ser-Val-Leu-Asn, and (SEQ ID NO: 4) (iii) His(Ac)-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr- Thr-Arg-Leu-Arg-Lys-Gln-Met(O)-Ala-Val-Lys-Lys-Tyr- Leu-Asn-Ser-Val-Leu-Asn, wherein His(Ac) means N-acetyl histidine, and Met(O) means methionine oxide, and wherein the synthetic peptide has the biological activity of vasoactive intestinal peptide (VIP), and its administration to said patient leads to an improvement of lung functions in the patient compared to the administration with VIP under comparable conditions.